Opthalmologic uses of protein C

• US 6,656,490 B1
• Filed: 02/05/1996
• Issued: 12/02/2003
• Est. Priority Date: 05/04/1994
• Status: Expired due to Fees

• Current Assignee: University of Arkansas System
• Original Assignee: University of Arkansas System
• Inventors: Fink, Louis M., Brown, Harry H., Steinemann, Thomas L., Reis, Ivory A., Marlar, Richard A.
• Primary Examiner(s): PAGE, THURMAN K
• Application Number:
  US08/596,698
• Time in Patent Office: 2,857 Days
• Field of Search: 424/427, 424/422-426, 514/2, 514/21
• US Class Current: 424/427
• CPC Class Codes: A61K 38/4866 Protein C (3.4.21.69)
• CPC Class Codes: C12Y 304/21069 Protein C activated (3.4.21.69)

Abstract

The present invention provides a method of reducing intraocular fibrin comprising the administration of a pharmacologically effective dose of Protein C to an individual having elevated levels of intraocular fibrin. Also provided are various methods of preventing intraocular fibrin formation, treating intraocular diseases and reducing intraocular inflammation.

Claims

1. A method of reducing amounts of intraocular fibrin comprising the administration of a pharmacologically effective dose of Protein C so as to reduce the amount of intraocular fibrin in an individual having elevated levels of intraocular fibrin.

2. The method of claim 1, wherein said Protein C is selected from the group consisting of human Protein C and activated Protein C.

3. The method of claim 1, wherein said Protein C is administered in a concentration of from about 1.0 micrograms per milliliter to about 25.0 micrograms per milliliter.

4. The method of claim 1, wherein said administration of Protein C is selected from the group consisting of topical administration, subconjunctival injection, intracameral injection and intravitreal injection.

5. The method of claim 1, wherein said administration is concurrent with intraocular surgery.

6. The method of claim 5, wherein said intraocular surgery is selected from the group consisting of cataract surgery, vitrectomy, gluacoma filtering procedure, corneal transplantation and surgery for proliferative vitreoretinopathy.

7. The method of claim 1, further comprising the co-administration of a pharmacologically effective dose of Protein S to an individual having elevated levels of intraocular fibrin.

8. The method of claim 7, wherein said Protein S is administered in a concentration of from about 10.0 micrograms per milliliter to about 100.0 micrograms per milliliter.

9. A method of inhibiting intraocular fibrin formation comprising the administration of a pharmacologically effective dose of Protein C so as to reduce the amount of intraocular fibrin in an individual at risk for development of elevated levels of intraocular fibrin.

10. The method of claim 9, wherein said Protein C is selected from the group consisting of human Protein C and activated Protein C.

11. The method of claim 10, wherein said Protein C is administered in a concentration of from about 1.0 micrograms per milliliter to about 10.0 micrograms per milliliter.

12. The method of claim 9, wherein said administration of Protein C is selected from the group consisting of topical administration, subconjunctival injection, intracameral injection and intravitreal injection.

16. The method of claim 9, wherein said administration of Protein C is selected from the group consisting of topical administration, subconjunctival injection, intracameral injection and intravitreal injection.

17. The method of claim 16, wherein said intraocular disease is selected from the group consisting of uveitis, end-stage diabetes mellitis, anterior segment inflammatory states, post-traumatic states and retinopathy of prematurity.

18. The method of claim 9, wherein said administration is concurrent with intraocular surgery.

19. The method of claim 18, wherein said intraocular surgery is selected from the group consisting of cataract surgery, vitrectomy, gluacoma filtering procedure, corneal transplantation and surgery for proliferative vitreoretinopathy.

20. The method of claim 9, further comprising the co-administration of a pharmacologically effective dose of Protein S to an individual having elevated levels of intraocular fibrin.

21. The method of claim 20, wherein said Protein S is administered in a concentration of from about 10.0 micrograms per milliliter to about 100.0 micrograms per milliliter.

13. A method of treating intraocular disease comprising the administration of a pharmacologically effective dose of Protein C so as to reduce the amount of intraocular fibrin in an individual having said disease, said individual being at risk for development of elevated levels of intraocular fibrin.

14. The method of claim 13, wherein said Protein C is selected from the group consisting of human Protein C and activated Protein C.

15. The method of claim 13, wherein said Protein C is administered in a concentration of from about 1.0 micrograms per milliliter to about 25.0 micrograms per milliliter.